98% Cycloastragenol Powder

Cycloastragenol, a triterpene saponin compound, can be obtained from the hydrolysis of Astragaloside IV.

Cycloastragenol is the only telomerase activator discovered so far. By increasing telomerase and thereby delaying the shortening of telomeres, cycloastragenol is considered to have anti-aging effects.

The elongation of telomeres would allow each cell to last longer and also support the body's ability to produce new cells through more cell divisions. This would enable the body to replace dead and damaged cells for longer, potentially reducing aging.

Clinical research studies have demonstrated that CAG can activate telomerase in humans. These properties of CAG led to the belief that CAG could be used as an antiaging agent. 

Later research studies were focused primarily on assessing whether CAG could actually defy the signs of aging. In various studies CAG has been shown to reduce fine lines and wrinkles, boost immunity and improve vision.

While these studies demonstrate CAG may be beneficial in increasing healthspan, no studies have yet conclusively demonstrated CAG’s ability to extend lifespan in humans. 

1. It has significant telomerase activation effect, thereby delaying the shortening of telomeres, and ultimately plays an anti-aging effect. In addition, cycloastragalus also has potential antiviral, protective lung damage, antidepressant, antihyperlipidemia and other pharmacological activities.

2. It can effectively improve the skin thickening and infiltration of inflammatory factors in the diseased skin area. For imiquimod-induced psoriasis, it can significantly improve the skin thickening in the diseased area, and at the same time, dose-dependently reduce the concentration of the skin in the diseased area. Levels of infiltrating inflammatory factors.

3. It has a certain delaying effect on the progression of aging-related diseases such as osteoporosis, cardiovascular disease, Alzheimer's disease, and stroke.

4. Cycloastraganol can promote melanin synthesis at both the cellular and animal levels, and has a good therapeutic effect on vitiligo. Its mechanism may be related to the activation of the p38 signaling pathway.

5. Cycloastragenol can increase the expression of TERT in brain tissue after cerebral ischemia-reperfusion, which is speculated to be one of the mechanisms by which cycloastragenol reduces cerebral ischemia-reperfusion injury. Cycloastragenol can also inhibit neuronal apoptosis during cerebral ischemia-reperfusion, which is achieved by promoting TERT expression.